SARILUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2017)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AC14
UNII: NU90V55F8I

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Interleukin-6 receptor alpha subunit antagonist PubMed
Primary Target
Interleukin-6 receptor, α subunit

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 4 D001172 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Polymyalgia Rheumatica 3 D011111 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Giant Cell Arteritis 3 D013700 ClinicalTrials
Mastocytosis, Systemic 2 D034721 ClinicalTrials
Arthritis, Juvenile 2 D001171 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Spondylitis, Ankylosing 2 D013167 ClinicalTrials
Scleroderma, Localized 1 D012594 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
24.23
Injury, poisoning and procedural complications
14.51
Skin and subcutaneous tissue disorders
12.97
Musculoskeletal and connective tissue disorders
8.29
Respiratory, thoracic and mediastinal disorders
6.03
Infections and infestations
5.52
Gastrointestinal disorders
4.84
Immune system disorders
4.72
Nervous system disorders
4.05
Vascular disorders
2.55
Investigations
2.31
Cardiac disorders
2.23

Cross References

Resources Reference
CAS NUMBER 1189541-98-7
ChEMBL CHEMBL2108730
FDA SRS NU90V55F8I
Guide to Pharmacology 7999
CONTENTS